Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Telemedicine Follow-Up for Intravitreal Bevacizumab Injection in the Stanford University Network for Diagnosis of Retinopathy of Prematurity (SUNDROP) Cohort. Clinical ophthalmology (Auckland, N.Z.) Ji, M. H., Callaway, N. F., Greven, M. A., Vail, D., Moshfeghi, D. M. 2020; 14: 1161-1163

Abstract

Telemedicine has emerged as a potential solution to face the disproportion between infants that need to be screened for ?retinopathy of ?prematurity (ROP) and the lack of ophthalmologists. We evaluated its utility in the follow-up after off-label intravitreal injection of bevacizumab. None of the treated infants ended up with bad anatomic outcome. Telemedicine is an alternative safe method to monitor patients after treatment.

View details for DOI 10.2147/OPTH.S250361

View details for PubMedID 32431486

View details for PubMedCentralID PMC7200391